Show simple item record

dc.contributor.authorReck, M
dc.contributor.authorLiu, SV
dc.contributor.authorMansfield, AS
dc.contributor.authorMok, TSK
dc.contributor.authorScherpereel, A
dc.contributor.authorReinmuth, N
dc.contributor.authorGarassino, MC
dc.contributor.authorCarpeno, JD
dc.contributor.authorCalifano, Raffaele
dc.contributor.authorNishio, M
dc.contributor.authorOrlandi, F
dc.contributor.authorAlexander, JAA
dc.contributor.authorLeal, TA
dc.contributor.authorCheng, Y
dc.contributor.authorLee, JS
dc.contributor.authorLam, S
dc.contributor.authorMcCleland, M
dc.contributor.authorDeng, Y
dc.contributor.authorPhan, S
dc.contributor.authorHorn, L
dc.date.accessioned2019-12-09T17:23:31Z
dc.date.available2019-12-09T17:23:31Z
dc.date.issued2019en
dc.identifier.citationReck M, Liu SV, Mansfield AS, Mok TSK, Scherpereel A, Reinmuth N, et al. 1736OI Mpower133: Updated overall survival (OS) analysis of first-line (1L) atezolizumab (atezo) + carboplatin + etoposide in extensive-stage SCLC (ES-SCLC). Annals of Oncology. 2019;30(Supplement_5):710.en
dc.identifier.doi10.1093/annonc/mdz264en
dc.identifier.urihttp://hdl.handle.net/10541/622595
dc.language.isoenen
dc.relation.urlhttps://dx.doi.org/10.1093/annonc/mdz264en
dc.titleIMpower133: Updated overall survival (OS) analysis of first-line (1L) atezolizumab (atezo) plus carboplatin plus etoposide in extensive-stage SCLC (ES-SCLC)en
dc.typeMeetings and Proceedingsen
dc.contributor.departmentThoracic Oncology, Lung Clinic Grosshansdorf, Airway Research Center North, German Center of Lung Research, Grosshansdorf, Germany.en
dc.identifier.journalAnnals of Oncologyen
refterms.dateFOA2020-01-21T20:19:14Z


Files in this item

Thumbnail
Name:
mdz264.pdf
Size:
133.5Kb
Format:
PDF
Description:
From UNPAYWALL. Conference abstract

This item appears in the following Collection(s)

Show simple item record